Announcements

Intimation about Transcript of the Earnings Call held on Tuesday, November 03, 2020 at 12.00 Noon local time of Indian and Overseas Investors, post declaration of the Company’s Unaudited Financial Results (stand-alone & consolidated) for the Quarter / Half Year ended 30-09-2020. Click here

Intimation about conference call for Indian and Overseas Investors to be held on Tuesday, November 03, 2020 to discuss about Unaudited financial results (Stand-alone and Consolidated) for the quarter / half year ended 30-09-2020. Click here to see the invite

Intimation of outcome of the Board Meeting held on October 28, 2020, as follows:

1) The Board approved Unaudited Financial Results (both Stand-alone and Consolidated) for the quarter / half year ended on 30-09-2020.

2) The Board declared an interim dividend of Rs.10/- per share for FY 2020-21.

3) The Board took on record the following changes of the Key Managerial Personnel:

i. Dr. A. Velumani, Chairman, has been reappointed as Managing Director

ii. Mr. A. Sundararaju, has been reappointed as Executive Director & Chief Financial Officer

iii. Mr. Arindam Haldar has been appointed as Chief Executive Officer.

Intimation about Board Meeting scheduled to be held on Wednesday, October 28, 2020, inter alia, to consider and approve the unaudited financial results (both Stand-alone and Consolidated) for the quarter / half year ended 30th September 2020, and to consider and decide on payment of interim dividend, if any, for the financial year 2020-21.

Intimation regarding business update on COVID-19 RT-PCR tests and COVID Antibody tests as on September 30, 2020.  The Company has also started RT-PCR tests from  its Laboratory situated at Gurgaon, Delhi and will create the same kind of facilities at Banglore and Kolkata. View Here

Intimation that Trading Window shall remain closed for Directors, Designated Employees and Connected Persons with effect from 1^st October, 2020 and will be reopened after 48 hours of date of announcement / declaration of Unaudited Financial Results for the quarter and half year ended September 30, 2020.

Intimation about the con-calls with the representatives of the following organizations:

(i) Nomura Asset Management Singapore Ltd., at 11.00 A.M. on Wednesday, September 23, 2020.

(ii) Acacia Partners, at 03.30 P.M. on Wednesday, September 23, 2020.

(iii) Earnest Innovation Partners Pvt. Ltd., at 11.00 A.M. on Thursday, September 24, 2020.

(iv) Abakkus Asset Manager LLP, at 03.30 P.M. on Thursday, September 24, 2020.

Intimation regarding appointment of Mr. Arindam Haldar as Chief Executive Officer (CEO) of the Company w.e.f. September 14, 2020. View Here

Intimation of decisions taken at the Board Meeting held on September 10, 2020, authorizing Dr. A. Velumani, Chairman & Managing Director, to identify and appoint a suitable candidate as a professional Chief Executive Officer for the Company. The Board also authorized Dr. A. Velumani, Chairman, to identify competent candidates for the positions of Managing Director, Executive Director, and other senior positions at his discretion.

Intimation about the Con-call (Zoom Meeting) with the representative(s) of Arisaig Partners, at 05.30 P.M. on Thursday, September 10, 2020.

Intimation about (i) 20th Annual General Meeting convened to be held on Tuesday, September 29, 2020 at 3.00 P.M. through Video Conferencing (VC) / Other Audio Visual Means (OAVM) & (ii) E-voting facility available to the Shareholders prior to the AGM and during the AGM.

Intimation about the Con-call with the representative(s) of Sylebra Capital Limited, at 11.30 A.M. on Monday, September 07, 2020.

Intimation about Board Meeting scheduled to be held on Thursday, September 10, 2020, inter alia, to discuss and decide about appointing a professional Chief Executive Officer of the Company who will function under the superintendence of the Board of Directors of the Company, headed by Dr. A. Velumani, PhD, Chairman & Managing Director.

Intimation of decisions taken at the Board Meeting held on July 31, 2020, about (i) approval of the Unaudited Financial Results (both Stand-alone and Consolidated) for the quarter ended on 30-06-2020, and (ii) decision not to declare any Interim Dividend considering the prevailing uncertain economic scenario.

Intimation about Board Meeting scheduled to be held on Friday, July 31, 2020, inter alia, to consider and approve the unaudited financial results (both Stand-alone and Consolidated) for the quarter ended 30th June 2020, and to consider and decide on payment of interim dividend, if any, for the financial year 2020-21.

Intimation about completion of 1,00,000 COVID-19 RT PCR tests in 108 days by Thyrocare at affordable cost and at minimum possible time in accordance with the relevant regulations, guidelines and instructions issued by ICMR from time to time. Also to note that the Company has started testing for COVID Antibodies from 28.06.2020 and have done more than 25,000 tests within a short span of 10 days.View Here

Intimation that Trading Window shall remain closed for Directors, Designated Employees and Connected Persons with effect from 1^st July, 2020 and will be reopened after 48 hours of date of announcement / declaration of Unaudited Financial Results for the Quarter ended June 30, 2020.

Intimation of decisions taken at the Board Meeting held on May 23, 2020, about i) approval of the Audited Financial Statements (both Stand-alone and Consolidated) for the quarter and the whole year ended 31-03-2020, ii) deferring recommendation of final dividend for the FY 2019-20, and iii) granting of Stock Options to the eligible employees for FY 2019-20.

Intimation about Board Meeting scheduled to be held on Saturday, May 23, 2020, inter alia, to consider and approve the audited financial results (both Stand-alone and Consolidated) for the year ended 31st March 2020, to consider recommending final dividend, if any, for the financial year 2019-20, and to consider granting of stock options to employees for 2019-20.

Intimation about closure of Trading Window for Directors, Employees and Connected Persons from April 01, 2020 (as already announced) up to end of the day on May 26, 2020.

Intimation that Trading Window shall remain closed for Directors, Designated Employees and Connected Persons with effect from 1^st April, 2020 and will be reopened after 48 hours of date of announcement / declaration of Audited Financial Results for the Quarter and Year ended March 31, 2020.

Intimation about the con-calls with the representatives of the following organisations to discuss the impact of COVID-19:

(i) ICICI Prudential AMC, at 02.30 P.M. on Tuesday, March 31, 2020.

(ii) Premji Invest, at 03.30 P.M. on Tuesday, March 31, 2020.

(iii) Nippon India Mutual Fund, at 04.00 P.M. on Wednesday, April 01, 2020.

Intimation about Con-call arranged by PhillipCapital (India) Pvt. Ltd. with Dr. A. Velumani, Chairman, Managing Director and CEO of our company, to discuss on ‘Covid-19 and its impact on Indian Healthcare’, at 02.30 P.M. today, i.e. Wednesday, March 18, 2020, and deferring of Con-call arranged through Prabhudas Lilladher Pvt. Ltd. on the same topic.

Intimation about Con-call through Prabhudas Lilladher (P) Limited, on ‘Covid-19 and Diagnostics’, at 04.00 P.M., today i.e. Wednesday, March 18, 2020.

Intimation about meeting of representative(s) of Crescita Investment Management Pvt. Ltd. with us at 04.00 P.M. on Wednesday, March 11, 2020 at the Corporate Office of the Company.

Intimation about the following forthcoming Analyst meetings:

(i) Meeting with the representative(s) of J. P. Morgan India Private Limited, at 11.30 A.M. on Wednesday, March 11, 2020.

(ii) Meeting with the representative(s) of Aditya Birla Capital, at 11.00 A.M. on Thursday, March 12, 2020.

(iii) Meeting with the representative(s) of Hill Fort Capital Partners Limited, at 11.30 A.M. on Wednesday, March 18, 2020.

Intimation about the following forthcoming Analyst meetings:

(i) Meeting with the representative(s) of QRC Investment Advisors LLP, at 11.30 A.M. on Monday, February 24, 2020.

(ii) Meeting with the representative(s) of SBI Mutual Fund, at 3.00 P.M. on Monday, February 24, 2020.

(iii) Meeting with the representative(s) of Ampersand Capital Partners, at 11.30 A.M. on Tuesday, February 25, 2020.

(iv) Meeting with the representative(s) of Wallfort Financial Services Limited, at 4.00 P.M. on Tuesday, February 25, 2020.

Press Release – Launching of marketing Joint Venture by Thyrocare for Datar Cancer Genetics, for early detection of 16 types of cancer.View Here

Intimation about the following forthcoming Con-call:

(i) Con-call with the representative(s) of Eternity Capital Management Limited, at 11.00 A.M. on Monday, February 17, 2020.

(ii) Con-call with the representative(s) of Mirabilis Investment Trust, at 04.00 P.M. on Monday, February 17, 2020.

Update about closure of two centres (Surat and Baroda) of Nueclear Healthcare Limited, wholly owned subsidiary of the Company.